Ultrasound vs. Endometrial Biopsy: What Can Each Test Establish?

An ultrasound shows the structure and thickness of the uterine lining. An endometrial biopsy examines tissue from that lining for abnormal cells.

The tests answer different questions, and neither result should be interpreted without considering the bleeding that prompted the evaluation.

A thin lining or a benign biopsy can be reassuring in the right setting. Persistent or recurrent bleeding still needs a clinical explanation, including whether further testing is needed to assess possible endometrial cancer.

What Ultrasound Can Show

A transvaginal ultrasound uses a probe placed in the vagina to create images of the uterus and nearby structures. It can measure the endometrium, the lining inside the uterus, and help identify polyps, fibroids, or other abnormalities.

The measurement is usually reported in millimeters. Its meaning depends on menopausal status, symptoms, medications, and whether the lining was fully visible.

Ultrasound cannot establish whether a thickened area contains cancer cells. Benign changes, an overgrowth called hyperplasia, and cancer can produce overlapping appearances. Tissue examination may be needed to distinguish them.

What an Endometrial Biopsy Can Establish

An office biopsy usually passes a thin suction tube through the cervix into the uterus to collect tissue. A pathologist examines the sample under a microscope.

The American Cancer Society explains the role of endometrial tissue sampling in diagnosis. A sample may show benign tissue, hyperplasia, precancerous changes, or cancer. If cancer is identified, the report can provide information about its type and grade.

A biopsy does not by itself establish the full stage of a cancer. It also evaluates the tissue obtained, not every part of the uterine lining.

Test	What it helps establish	Important limitation
Transvaginal ultrasound	The lining’s thickness, appearance, and possible structural abnormalities	Images do not provide a tissue diagnosis
Endometrial biopsy	Whether the sampled tissue contains abnormal or cancerous cells	A small sample can miss a localized abnormality
Hysteroscopy with targeted biopsy	What an abnormal area looks like and what its sampled tissue contains	The findings still require clinical and pathology interpretation

The 4 mm Rule Changed in 2026

ACOG’s April 2026 update on postmenopausal bleeding recommends both transvaginal ultrasound and tissue sampling in the initial evaluation of most patients.

Ultrasound alone remains an option for selected patients with a single bleeding episode, a fully visualized lining no thicker than 4 mm, no strongly associated cancer risk factors, and reliable access to prompt gynecologic follow-up. They also need counseling that continued or recurrent bleeding requires immediate reassessment.

The update revises earlier guidance that more broadly allowed ultrasound alone as the first evaluation when the lining measured 4 mm or less.

A thin measurement is therefore not a universal reason to skip biopsy.

A Poorly Seen Lining Is Not the Same as a Normal Lining

The report should distinguish a reliably measured lining from one that could not be adequately assessed.

Fibroids, uterine position, prior procedures, and other factors can interfere with visualization. The 2026 ISUOG consensus on endometrial ultrasound explains how image quality and the appearance of the lining affect interpretation.

A measurement from an incompletely seen lining should not be treated as equivalent to a clearly visualized thin endometrium. The clinician needs to decide whether additional imaging, tissue assessment, or hysteroscopy is appropriate.

Medication history also matters. Tamoxifen can alter the lining’s appearance. Report bleeding and tell the gynecologist about tamoxifen or hormone therapy, but do not stop prescribed cancer treatment on your own.

When Hysteroscopy Helps Answer the Remaining Question

Hysteroscopy allows a clinician to inspect the uterine cavity and sample a visible abnormality. The American Cancer Society describes how hysteroscopy can investigate bleeding and obtain tissue.

A 2026 joint society guideline on visually directed biopsy favors sampling under hysteroscopic visualization when tissue assessment is indicated, particularly when a focal abnormality is suspected or earlier imaging or sampling is inconclusive. It also acknowledges limitations in the supporting evidence.

Dilation and curettage, or D&C, collects tissue after the cervix is dilated and may be combined with hysteroscopy. D&C performed without direct visualization is still a form of blind sampling.

Saline infusion sonohysterography uses fluid during ultrasound to outline the uterine cavity more clearly. It can help locate a structural problem, but imaging does not replace microscopic examination when tissue diagnosis is needed.

The choice is not simply whether to repeat a test. It is which method can answer the question the earlier evaluation left unresolved.

What to Ask When Bleeding Continues

Tell your gynecologist if bleeding persists or returns after testing. Bleeding and spotting are among the symptoms associated with endometrial cancer, although many noncancerous conditions can also cause them.

Ask for the actual reports. “Insufficient for diagnosis” and “limited visualization” identify limitations that need interpretation. “Clinical correlation” means the findings should be considered alongside the symptoms and other information; that phrase alone does not prove the result is abnormal.

Heavy bleeding accompanied by faintness, severe weakness, or other concerning symptoms needs urgent medical assessment. Do not postpone clinical follow-up while gathering records or seeking legal advice.

New York Deadlines for a Missed Endometrial Cancer Diagnosis

CPLR 214-a generally sets a two-year-and-six-month medical malpractice period, with specific provisions for negligent failure to diagnose cancer or a malignant tumor.

For a qualifying cancer claim, the discovery branch concerns when the patient knew or reasonably should have known both of the alleged negligence and that it caused injury. It includes a seven-year restriction measured from the alleged act or omission.

The special period runs from the later of qualifying discovery or the last treatment in a qualifying course of continuous treatment. An ongoing relationship alone does not establish continuous treatment.

This is not a rule giving everyone two and a half years from diagnosis or automatically seven years to sue. The applicable dates, statutory branch, and any toll must be evaluated.

Public-entity claims may have additional notice requirements and different lawsuit deadlines. Where General Municipal Law 50-e applies, notice is generally due within 90 days after the claim arises; in wrongful death actions, that notice period runs from appointment of the estate representative. Different public entities can follow different frameworks.

If the patient died, EPTL 5-4.1 generally gives the estate’s personal representative two years from death for a wrongful death action. Death does not automatically revive an already time-barred underlying claim.

Talk With a New York Cancer Lawyer About Missed Follow-Up

If bleeding continued after a reassuring scan, a benign biopsy, or an insufficient sample, and cancer was later diagnosed, you can ask Porter Law Group’s New York cancer lawyers about a possible claim.

The review would examine what the tests established, what remained unresolved, and whether an alleged failure in follow-up caused additional harm.

Call 833-888-LATE, email info@porterlawteam.com, or request a free case evaluation. Ongoing bleeding should be medically assessed independently of any legal inquiry.

This article is for informational and educational purposes only. It is not a substitute for medical advice from a qualified healthcare provider or legal advice based on your specific circumstances.

Attorney advertising. Contacting Porter Law Group does not create an attorney-client relationship.

Frequently Asked Questions

Does a lining of 4 mm or less rule out endometrial cancer?

No. A thin measurement is not an absolute exclusion. ACOG’s 2026 update recommends ultrasound plus tissue sampling for most patients with postmenopausal bleeding, reserving ultrasound alone for selected circumstances. Continued or recurrent bleeding requires reassessment rather than reassurance based only on the earlier measurement.

Can an endometrial biopsy miss a polyp or a small cancer?

Yes. A blind office biopsy samples only part of the lining and may miss a localized abnormality. The significance of a benign result depends on the imaging and symptoms. If a focal lesion is suspected or bleeding continues, the clinician may recommend hysteroscopy with targeted sampling.

Is an insufficient biopsy the same as a negative biopsy?

No. An insufficient result means the sample did not provide enough suitable tissue for the intended assessment. It does not establish that cancer was excluded. Further management depends on the bleeding, ultrasound findings, risk factors, and the pathologist’s report, rather than an automatic assumption that every patient needs the same procedure.

Does the 4 mm cutoff apply before menopause?

No. The lining naturally changes during the menstrual cycle, so the postmenopausal threshold should not be used as a universal rule before menopause. Decisions about sampling depend on the bleeding pattern, age, risk factors, and response to treatment, not a single ultrasound measurement considered in isolation.

Does a later cancer diagnosis prove the first test was negligent?

No. Tests have limitations, and a later diagnosis does not establish what should have been detectable earlier. A claim needs evidence that the evaluation or follow-up fell below accepted care and that this departure caused additional harm. The original records and qualified medical review are central to that assessment.